The progression of chimeric antigen receptor modified T cells in malignant tumor / 国际肿瘤学杂志
Journal of International Oncology
; (12): 495-499, 2014.
Article
de Zh
| WPRIM
| ID: wpr-454288
Bibliothèque responsable:
WPRO
ABSTRACT
Recentyearshavewitnessedmuchprogressinbothbasicresearchandclinicaltrialsregar-ding cancer immunotherapy with chimeric antigen receptor (CAR)-engineered T cells.CAR combine the varia-ble regions of a specific monoclonal antibody (scFv)with the CD3ζendodomain.The extracellular domain of CAR-engineered T cells directly dock to the tumor-associated antigen (TAA).When T cells bind to target anti-gens,they mediated redirected cytotoxicity and secrete a series of cytokines such as Perforin,Granzyme,Inter-feron-γ(IFN-γ)and Tumor necrosis factor-α(TNF-α),which would eventually lead to the necrosis of tumor cells.Although the antitumor response of the CAR-engineered T cells is considered as successful and surpri-sing,it should be noted that some safety issues have been observed in other several basic researches and clinical trials.This overview focuses upon the utility and safety of the CAR-engineered T cells.
Texte intégral:
1
Indice:
WPRIM
langue:
Zh
Texte intégral:
Journal of International Oncology
Année:
2014
Type:
Article